Documents

MEB Regulatory Science Day 2017

Publication | 23-12-2016

Classification overview legal status of supply NSAIDs

The MEB has determined a classification system for OTC anti-inflammatories (NSAIDs).

Policy document | 24-11-2016

Assessment report DHA-rich algal oil, applicant NovoSana (Europe) B.V.

A report on the assessment of DHA-rich algal oil by the company NovoSana (Europe) B.V. for substantial equivalence to DHA-rich ...

Report | 02-11-2016

Assessment report Chia seed, applicant DFInternational BV

A report on the assessment of chia seed by the company DFInternational B.V. for substantial equivalence to chia seed, which has ...

Report | 19-10-2016

MEB 41: MEB policy concerning marketing authorisations without Dutch translations of the product information and/or mock-ups

The MEB is aware of the fact that medicinal products are not always marketed immediately after authorisation. Following the ...

Policy document | 18-10-2016

Assessment report 2’-fucosyllactose, applicant Jennewein Biotechnologie GmbH

A report on the initial assessment of 2’-fucosyllactose by the company Jennewein Biotechnologie GmbH.

Report | 03-06-2016

Heads of Medicines Agencies: Heads and IT directors meeting

Publication | 01-06-2016

HMA human stakeholders meeting

Publication | 31-05-2016

Code of conduct and integrity policy for the Medicines Evaluation Board (MEB)

The MEB places importance to the integrity, impartiality and independence of its Board members and staff to guarantee the quality ...

Publication | 04-05-2016

Influenza strains: Dutch translation of active substances 2016/2017

The Medicines Evaluation Board (MEB) has confirmed the Dutch translation for the active substances for influenza strains for the ...

Publication | 14-04-2016